Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892407597> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2892407597 endingPage "1424" @default.
- W2892407597 startingPage "1423" @default.
- W2892407597 abstract "Antibodies targeting PD-1 (eg, nivolumab and pembrolizumab), or its ligand, PD-L1 (eg, atezolizumab), are approved as second-line therapy in non-small-cell lung cancer (NSCLC). The American Society of Clinical Oncology's 2017 Clinical Practice Guideline 1 Hanna N Johnson D Temin S et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017; 35: 3484-3515 Crossref PubMed Scopus (437) Google Scholar recommended pembrolizumab as second-line therapy in patients with NSCLC with PD-L1 tumour proportion scores of more than 1% (ie, patients with PD-L1 expression in 1% or more tumour cells). 1 Hanna N Johnson D Temin S et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017; 35: 3484-3515 Crossref PubMed Scopus (437) Google Scholar In the guideline, nivolumab and atezolizumab were also recommended as second-line therapy in patients with NSCLC with any level of PD-L1 expression. Other T-cell checkpoint inhibitors were not recommended in NSCLC. 1 Hanna N Johnson D Temin S et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017; 35: 3484-3515 Crossref PubMed Scopus (437) Google Scholar Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 studyCompared with docetaxel, avelumab did not improve overall survival in patients with platinum-treated PD-L1-positive NSCLC, but had a favourable safety profile. Full-Text PDF" @default.
- W2892407597 created "2018-10-05" @default.
- W2892407597 creator A5044887899 @default.
- W2892407597 creator A5084359163 @default.
- W2892407597 date "2018-11-01" @default.
- W2892407597 modified "2023-09-27" @default.
- W2892407597 title "Avelumab in non-small-cell lung cancer" @default.
- W2892407597 cites W2198093519 @default.
- W2892407597 cites W2289073238 @default.
- W2892407597 cites W2293531514 @default.
- W2892407597 cites W2635951006 @default.
- W2892407597 cites W2762777471 @default.
- W2892407597 cites W2767055857 @default.
- W2892407597 cites W2804812017 @default.
- W2892407597 cites W2805660084 @default.
- W2892407597 cites W2893602866 @default.
- W2892407597 cites W4242460399 @default.
- W2892407597 doi "https://doi.org/10.1016/s1470-2045(18)30683-1" @default.
- W2892407597 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30262188" @default.
- W2892407597 hasPublicationYear "2018" @default.
- W2892407597 type Work @default.
- W2892407597 sameAs 2892407597 @default.
- W2892407597 citedByCount "5" @default.
- W2892407597 countsByYear W28924075972019 @default.
- W2892407597 countsByYear W28924075972020 @default.
- W2892407597 countsByYear W28924075972021 @default.
- W2892407597 countsByYear W28924075972023 @default.
- W2892407597 crossrefType "journal-article" @default.
- W2892407597 hasAuthorship W2892407597A5044887899 @default.
- W2892407597 hasAuthorship W2892407597A5084359163 @default.
- W2892407597 hasConcept C121608353 @default.
- W2892407597 hasConcept C126322002 @default.
- W2892407597 hasConcept C142724271 @default.
- W2892407597 hasConcept C143998085 @default.
- W2892407597 hasConcept C2775949291 @default.
- W2892407597 hasConcept C2776256026 @default.
- W2892407597 hasConcept C2776598537 @default.
- W2892407597 hasConcept C2777381376 @default.
- W2892407597 hasConcept C2777701055 @default.
- W2892407597 hasConcept C2780030458 @default.
- W2892407597 hasConcept C2780057760 @default.
- W2892407597 hasConcept C2780182762 @default.
- W2892407597 hasConcept C2781190966 @default.
- W2892407597 hasConcept C71924100 @default.
- W2892407597 hasConceptScore W2892407597C121608353 @default.
- W2892407597 hasConceptScore W2892407597C126322002 @default.
- W2892407597 hasConceptScore W2892407597C142724271 @default.
- W2892407597 hasConceptScore W2892407597C143998085 @default.
- W2892407597 hasConceptScore W2892407597C2775949291 @default.
- W2892407597 hasConceptScore W2892407597C2776256026 @default.
- W2892407597 hasConceptScore W2892407597C2776598537 @default.
- W2892407597 hasConceptScore W2892407597C2777381376 @default.
- W2892407597 hasConceptScore W2892407597C2777701055 @default.
- W2892407597 hasConceptScore W2892407597C2780030458 @default.
- W2892407597 hasConceptScore W2892407597C2780057760 @default.
- W2892407597 hasConceptScore W2892407597C2780182762 @default.
- W2892407597 hasConceptScore W2892407597C2781190966 @default.
- W2892407597 hasConceptScore W2892407597C71924100 @default.
- W2892407597 hasIssue "11" @default.
- W2892407597 hasLocation W28924075971 @default.
- W2892407597 hasLocation W28924075972 @default.
- W2892407597 hasOpenAccess W2892407597 @default.
- W2892407597 hasPrimaryLocation W28924075971 @default.
- W2892407597 hasRelatedWork W2524203899 @default.
- W2892407597 hasRelatedWork W2748547721 @default.
- W2892407597 hasRelatedWork W2765949442 @default.
- W2892407597 hasRelatedWork W2884534038 @default.
- W2892407597 hasRelatedWork W2894742494 @default.
- W2892407597 hasRelatedWork W2962238349 @default.
- W2892407597 hasRelatedWork W2968490685 @default.
- W2892407597 hasRelatedWork W3083344515 @default.
- W2892407597 hasRelatedWork W3118442307 @default.
- W2892407597 hasRelatedWork W4293000834 @default.
- W2892407597 hasVolume "19" @default.
- W2892407597 isParatext "false" @default.
- W2892407597 isRetracted "false" @default.
- W2892407597 magId "2892407597" @default.
- W2892407597 workType "article" @default.